Expanding the Activity of Tissue Inhibitors of Metalloproteinase (TIMP)-1 against Surface-Anchored Metalloproteinases by the Replacement of Its C-Terminal Domain: Implications for Anti-Cancer Effects.

Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett (2016) 0.79

Direct expression of active human tissue inhibitors of metalloproteinases by periplasmic secretion in Escherichia coli. Microb Cell Fact (2017) 0.75

Ensnaring membrane type 1-matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase (TIMP)-2 using the haemopexin domain of the protease as a carrier: a targeted approach in cancer inhibition. Oncotarget (2017) 0.75

In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc (2007) 12.39

Primary bioassay of human tumor stem cells. Science (1977) 9.69

The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol (1988) 5.84

Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med (2002) 3.74

TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett (1998) 3.04

Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17

Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta (2009) 2.04

The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett (2000) 2.03

The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol (2002) 1.99

Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J (2006) 1.93

The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol (2010) 1.71

Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann N Y Acad Sci (1999) 1.68

Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol (2009) 1.65

The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol (2008) 1.60

Proteomic identification of matrix metalloproteinase substrates in the human vasculature. Circ Cardiovasc Genet (2012) 1.54

Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE). J Biol Chem (1999) 1.41

Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci (2010) 1.41

Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem (2004) 1.37

Cytokine functions of TIMP-1. Cell Mol Life Sci (2013) 1.23

Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem (2000) 1.15

Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling. Proc Natl Acad Sci U S A (2012) 1.09

Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J Biol Chem (2007) 1.09

Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2. J Mol Biol (2006) 1.07

Critical role of transient activity of MT1-MMP for ECM degradation in invadopodia. PLoS Comput Biol (2013) 1.07

Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. Biochem Biophys Res Commun (2001) 1.06

Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer (2003) 1.02

Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem (2003) 1.02

MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer (2014) 1.02

Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem (2012) 0.97

NMR structure of tissue inhibitor of metalloproteinases-1 implicates localized induced fit in recognition of matrix metalloproteinases. J Mol Biol (2000) 0.97

Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. Biochem J (2002) 0.96

MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBS Lett (2014) 0.94

AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther (2004) 0.91

The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB J (2012) 0.90

A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res (2004) 0.85

Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes. PLoS One (2013) 0.84

Proteomic approaches to uncover MMP function. Matrix Biol (2015) 0.82

Synthesis and screening of N-alkyl hydroxamates for inhibition of cancer cell proliferation. Comb Chem High Throughput Screen (2006) 0.80

Overexpression of TIMP-1 mediated by recombinant adenovirus in hepatocellular carcinoma cells inhibits proliferation and invasion in vitro. Hepatobiliary Pancreat Dis Int (2006) 0.79